Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision tag updated from v3.6.6 to v3.7.0, indicating a minor update to the page metadata.SummaryDifference0.0%

- Check8 days agoChange Detected- Tel Litwinsky, Israel, 52621 was added as a study site. - Qiryat Krinitzi, Israel, 52621 was removed from the participating sites.SummaryDifference0.1%

- Check15 days agoChange DetectedThe Israeli recruitment site Tel Litwinsky was removed and a new site, Qiryat Krinitzi, was added, updating the list of enrollment locations in Israel.SummaryDifference0.1%

- Check22 days agoChange DetectedThe page now includes a 2019 U.S. NIH grant/contract acknowledgment and adds a publication citation about the overall survival findings related to EV-302. These additions provide background references and funding context for the study.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page footer now displays Revision: v3.6.5, replacing the previous v3.6.4, signaling a software update.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page now includes a new revision line: Revision: v3.6.4, and the previous Revision: v3.6.3 line was removed. This marks a new page revision rather than any substantive content change.SummaryDifference0.0%

Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.